<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width,initial-scale=1" />
  <title>Cape Porpoise Clinical Consulting, LLC</title>
  <meta name="description" content="Clinical and regulatory consulting for early-stage biotech. Strategy to execution." />
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Libre+Baskerville:ital,wght@0,400;0,700;1,400&family=DM+Sans:opsz,wght@9..40,400;9..40,500;9..40,600&display=swap" rel="stylesheet">
  <script src="https://cdnjs.cloudflare.com/ajax/libs/d3/7.8.5/d3.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/topojson/3.0.2/topojson.min.js"></script>

  <style>
    :root {
      --ink: #0e1219;
      --paper: #f7f4ef;
      --muted: #5a6a8a;
      --accent: #1a2d6e;
      --rule: #d4cfc7;
      --serif: 'Libre Baskerville', Georgia, serif;
      --sans: 'DM Sans', system-ui, sans-serif;
    }

    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
    html { scroll-behavior: smooth; }

    body {
      font-family: var(--sans);
      background: var(--paper);
      color: var(--ink);
      line-height: 1.6;
    }

    nav {
      position: sticky;
      top: 0;
      z-index: 100;
      background: rgba(247,244,239,.95);
      backdrop-filter: blur(10px);
      border-bottom: 1px solid var(--rule);
      padding: 0 48px;
      display: flex;
      justify-content: space-between;
      align-items: center;
      height: 200px;
    }

    .brand {
      display: flex;
      align-items: center;
      text-decoration: none;
      color: var(--ink);
    }

    .brand-logo {
      height: 240px;
      width: auto;
      display: block;
    }

    .nav-links { display: flex; gap: 24px; list-style: none; }

    .nav-links a {
      font-size: 12px;
      font-weight: 600;
      letter-spacing: .07em;
      text-transform: uppercase;
      color: var(--muted);
      text-decoration: none;
      transition: color .15s;
    }

    .nav-links a:hover { color: var(--ink); }

    .hero {
      min-height: 84vh;
      display: flex;
      flex-direction: column;
      justify-content: flex-end;
      padding: 72px 48px;
      border-bottom: 1px solid var(--rule);
    }

    .eyebrow {
      font-size: 11px;
      font-weight: 600;
      letter-spacing: .18em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 22px;
      display: flex;
      align-items: center;
      gap: 12px;
      opacity: 0;
      animation: up .6s ease .1s forwards;
    }

    .eyebrow::before {
      content: '';
      width: 24px;
      height: 1px;
      background: var(--muted);
      flex-shrink: 0;
    }

    h1 {
      font-family: var(--serif);
      font-size: clamp(34px, 5.5vw, 72px);
      line-height: 1.08;
      letter-spacing: -.02em;
      max-width: 820px;
      margin-bottom: 32px;
      opacity: 0;
      animation: up .7s ease .2s forwards;
    }

    h1 em { font-style: italic; color: var(--accent); }

    .cta-row {
      display: flex;
      gap: 14px;
      align-items: center;
      opacity: 0;
      animation: up .7s ease .33s forwards;
    }

    .btn {
      background: var(--accent);
      color: #fff;
      padding: 13px 24px;
      border-radius: 3px;
      text-decoration: none;
      font-size: 13px;
      font-weight: 600;
      letter-spacing: .04em;
      transition: opacity .15s;
    }

    .btn:hover { opacity: .85; }

    section { border-bottom: 1px solid var(--rule); }

    .row {
      max-width: 1060px;
      margin: 0 auto;
      padding: 72px 48px;
      display: grid;
      grid-template-columns: 180px 1fr;
      gap: 52px;
    }

    .label {
      font-size: 10.5px;
      font-weight: 700;
      letter-spacing: .18em;
      text-transform: uppercase;
      color: var(--muted);
      padding-top: 4px;
    }

    .body-lg {
      font-size: 18px;
      line-height: 1.7;
      max-width: 660px;
      margin-bottom: 20px;
    }

    .body-lg:last-child { margin-bottom: 0; }

    .tag-group { margin-bottom: 28px; }
    .tag-group:last-child { margin-bottom: 0; }

    .tag-group-title {
      font-size: 10.5px;
      font-weight: 700;
      letter-spacing: .16em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 10px;
    }

    .tags { display: flex; flex-wrap: wrap; gap: 7px; }

    .tag {
      font-size: 13px;
      color: var(--ink);
      border: 1px solid var(--rule);
      padding: 5px 13px;
      border-radius: 999px;
      background: #fff;
    }

    .stat-grid {
      display: grid;
      gap: 1px;
      background: var(--rule);
      border: 1px solid var(--rule);
      border-radius: 5px;
      overflow: hidden;
    }

    .stat-grid-4 { grid-template-columns: repeat(4, 1fr); }
    .stat-grid-3 { grid-template-columns: repeat(3, 1fr); }

    .stat-cell {
      background: var(--paper);
      padding: 24px 20px;
      text-align: center;
    }

    .stat-cell strong {
      display: block;
      font-family: var(--serif);
      font-size: 36px;
      color: var(--accent);
      line-height: 1;
      margin-bottom: 8px;
    }

    .stat-cell span {
      font-size: 12.5px;
      color: var(--muted);
      line-height: 1.45;
    }

    .stat-cell .stat-label {
      font-size: 10px;
      font-weight: 700;
      letter-spacing: .13em;
      text-transform: uppercase;
      color: var(--ink);
      margin-bottom: 4px;
    }

    .stat-cell .stat-desc {
      font-size: 12px;
      color: var(--muted);
      line-height: 1.45;
    }

    .chart-label {
      font-size: 10.5px;
      font-weight: 700;
      letter-spacing: .16em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 14px;
      margin-top: 36px;
    }

    .chart-outer {
      border: 1px solid var(--rule);
      border-radius: 5px;
      padding: 24px 24px 0;
      background: var(--paper);
    }

    .bar-lbl {
      flex: 1;
      text-align: center;
      font-size: 11px;
      color: var(--muted);
      line-height: 1.5;
    }

    .chart-source {
      font-size: 11.5px;
      color: var(--muted);
      line-height: 1.55;
      padding: 12px 0 20px;
      border-top: 1px solid var(--rule);
      margin-top: 4px;
    }

    .svc-cols {
      display: grid;
      grid-template-columns: 1fr 1fr;
      gap: 1px;
      background: var(--rule);
      border: 1px solid var(--rule);
      border-radius: 5px;
      overflow: hidden;
      width: 100%;
    }

    .svc-col { background: var(--paper); padding: 32px 28px; }

    .svc-col-label {
      font-size: 10px;
      font-weight: 700;
      letter-spacing: .17em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 5px;
    }

    .svc-col-title {
      font-family: var(--serif);
      font-size: 19px;
      line-height: 1.2;
      margin-bottom: 7px;
    }

    .svc-desc {
      font-size: 13.5px;
      color: var(--muted);
      line-height: 1.55;
      margin-bottom: 20px;
      padding-bottom: 20px;
      border-bottom: 1px solid var(--rule);
    }

    .svc-list { list-style: none; display: flex; flex-direction: column; gap: 10px; }

    .svc-list li {
      font-size: 14px;
      color: var(--muted);
      line-height: 1.45;
      padding-left: 14px;
      position: relative;
    }

    .svc-list li::before {
      content: '';
      position: absolute;
      left: 0;
      top: 9px;
      width: 5px;
      height: 1px;
      background: var(--rule);
    }

    .about-body p {
      font-size: 15.5px;
      line-height: 1.78;
      color: var(--muted);
      margin-bottom: 16px;
      max-width: 660px;
    }

    .about-body p:last-child { margin-bottom: 0; }
    .about-body strong { color: var(--ink); font-weight: 600; }

    .about-body a {
      color: var(--accent);
      text-decoration: none;
      border-bottom: 1px solid var(--rule);
      transition: border-color .15s;
    }

    .about-body a:hover { border-color: var(--accent); }

    .contact-tag {
      font-family: var(--serif);
      font-size: 25px;
      line-height: 1.3;
      margin-bottom: 28px;
      max-width: 440px;
    }

    .contact-links { display: flex; flex-direction: column; margin-bottom: 24px; }

    .contact-link {
      display: flex;
      justify-content: space-between;
      align-items: center;
      font-size: 16px;
      font-weight: 500;
      color: var(--accent);
      text-decoration: none;
      padding: 13px 0;
      border-bottom: 1px solid var(--rule);
      transition: color .15s;
    }

    .contact-link:first-child { border-top: 1px solid var(--rule); }
    .contact-link:hover { color: #2d5f8a; }

    .arr { transition: transform .15s; }
    .contact-link:hover .arr { transform: translateX(4px); }

    .contact-note { font-size: 13px; color: var(--muted); line-height: 1.65; max-width: 380px; }

    footer {
      padding: 0 48px 48px;
      display: flex;
      flex-direction: column;
      align-items: center;
      gap: 0;
      border-top: 1px solid var(--rule);
    }

    .footer-logo {
      height: 160px;
      width: auto;
      display: block;
      margin: 40px auto 20px;
    }

    .footer-meta {
      width: 100%;
      display: flex;
      justify-content: space-between;
      flex-wrap: wrap;
      gap: 8px;
    }

    footer p { font-size: 12px; color: var(--muted); }

    .map-container {
      border: 1px solid var(--rule);
      border-radius: 5px;
      background: #cfe0ed;
      overflow: hidden;
      position: relative;
      margin-top: 24px;
    }
    #map-svg { width: 100%; height: auto; display: block; }
    .country-path { fill: #e2ddd7; stroke: #fff; stroke-width: 0.4; }
    .country-path.active {
      fill: var(--accent);
      stroke: #fff;
      stroke-width: 0.6;
      cursor: pointer;
      opacity: .85;
      transition: opacity .15s;
    }
    .country-path.active:hover { opacity: 1; }
    .map-tooltip {
      position: absolute;
      background: var(--ink);
      color: #fff;
      font-size: 11px;
      font-family: var(--sans);
      padding: 5px 10px;
      border-radius: 3px;
      pointer-events: none;
      opacity: 0;
      transition: opacity .1s;
      white-space: nowrap;
      z-index: 10;
    }
    .map-note {
      padding: 10px 16px;
      border-top: 1px solid var(--rule);
      background: var(--paper);
      font-size: 11px;
      color: var(--muted);
    }

    @keyframes up {
      from { opacity: 0; transform: translateY(20px); }
      to   { opacity: 1; transform: translateY(0); }
    }

    @media (max-width: 780px) {
      nav { padding: 0 20px; height: 120px; }
      .brand-logo { height: 100px; }
      .nav-links { display: none; }
      .hero { padding: 56px 20px; min-height: 68vh; }
      .row { grid-template-columns: 1fr; gap: 14px; padding: 52px 20px; }
      .svc-cols { grid-template-columns: 1fr; }
      .stat-grid-4 { grid-template-columns: 1fr 1fr; }
      .stat-grid-3 { grid-template-columns: 1fr 1fr; }
      footer { padding: 0 20px 24px; }
      .footer-logo { height: 100px; }
    }
  </style>
</head>

<body>

  <nav>
    <a class="brand" href="#top">
      <img class="brand-logo" src="CPCC_logo.png?v=2" alt="Cape Porpoise Clinical Consulting" />
    </a>
    <ul class="nav-links">
      <li><a href="#services">Services</a></li>
      <li><a href="#about">About</a></li>
      <li><a href="#industrytrends">Industry Trends</a></li>
      <li><a href="#contact">Contact</a></li>
    </ul>
  </nav>

  <div class="hero" id="top">
    <div class="eyebrow">Cape Porpoise Clinical Consulting, LLC &middot; Cambridge, MA</div>
    <h1>Helping lean biotech<br>chart a course to <em>meaningful clinical inflection points</em></h1>
    <div class="cta-row">
      <a class="btn" href="#contact">Get in touch</a>
    </div>
  </div>

  <!-- SERVICES -->
  <section id="services">
    <div class="row">
      <div class="label">What we do</div>
      <div>
        <p class="body-lg">CPCC works exclusively with <strong>early-to-mid clinical-stage biotech companies</strong> to efficiently navigate the path from candidate selection and confirmation to meaningful clinical inflection points: the data, regulatory decisions, and milestones that unlock program advancement and company growth.</p>
        <p class="body-lg">Whether you need a senior thought partner to support interactions with inbounds, the board, or regulatory authorities, or just need someone to build the clinical and regulatory infrastructure and get the work done, CPCC covers the full range. High-level development strategy through hands-on execution and submission-ready deliverables.</p>
        <p class="body-lg" style="margin-bottom:36px;">CPCC embeds directly with your team — large or small. For lean startups without a full clinical function, Amanda can serve as a fractional head of clinical development and regulatory affairs, owning strategy and execution end to end. For larger teams, she plugs in to lead specific workstreams, fill senior gaps, or provide surge capacity at critical moments.</p>

        <div class="svc-cols">
          <div class="svc-col">
            <div class="svc-col-label">Strategic</div>
            <div class="svc-col-title">Advisory and Consulting</div>
            <p class="svc-desc">Credible senior experience at the table for investor and regulatory interactions and program-level planning.</p>
            <ul class="svc-list">
              <li>Clinical and regulatory development strategy</li>
              <li>Trial design and endpoint selection</li>
              <li>FDA meeting preparation and participation</li>
              <li>Investor and board-level scientific and operational advisory</li>
              <li>Clinical and regulatory risk assessment</li>
              <li>Partnership and due diligence support</li>
            </ul>
          </div>
          <div class="svc-col">
            <div class="svc-col-label">Execution</div>
            <div class="svc-col-title">Clinical and Regulatory Work</div>
            <p class="svc-desc">Clinical/Regulatory deliverbles with quality built in.</p>
            <ul class="svc-list">
              <li>Regulatory correspondence and dossier authoring (briefing documents, IND amendments, etc) </li>
              <li>Clinical trial project management</li>
              <li>IND and CTA preparation and submission</li>
              <li>Data management and pharmacovigilance oversight</li>
              <li>Vendor oversight and operational problem-solving</li>
              <li>QC and narrative coherence review</li>
              <li>Medical writing: IBs, protocols, ICFs, CSRs</li>
            </ul>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- ABOUT + EXPERTISE -->
  <section id="about">
    <div class="row">
      <div class="label">About</div>
      <div>

        <div class="about-body" style="margin-bottom:48px;">
          <p>CPCC is led by <strong>Amanda McEwen</strong> — <a href="https://www.linkedin.com/in/amandamariegentilemcewen/" target="_blank" rel="noopener">LinkedIn</a> — SVP of Clinical Development at Salubris Biotherapeutics, where she leads the JK07 program, a first-in-class ErbB4 agonist in Phase 2b for heart failure.</p>
          <p>Amanda has spent her entire career working within small amd mid-size biotech, where the boundaries between functional areas are rarely as clean as an org chart suggests. That breadth — built from years of doing the work across functions, not just overseeing it — is what CPCC brings to client teams. She embeds fluidly with both small founding teams that need a full clinical function built out, and larger organizations that need senior capacity on a specific workstream or at a critical juncture.</p>
          <p>Her career highlights include key contributions to two FDA-approved therapies: <strong>Inbrija</strong>, for Parkinson's disease, and <strong>Rivfloza</strong>, for a rare genetic liver disease. She is especially passionate about early-phase development and has led several initiatives spanning preclinical research through clinical proof of concept.</p>
          <p>Beyond her industry role, Amanda serves as an Executive Fellow at Harvard Business School, helping educate and mentor newly minted entrepreneurs in the biotech space and also serves as adjunct faculty in Northeastern University's MS in Regulatory Affairs program, where she teaches classes on therapeutic product development and pharmacovigilance. Amanda is a current PhD candidate in Business Analytics at Bentley University. She earned her BA from the College of the Holy Cross and a Master of Research Methods in Psychology from the University of York in England.</p>
        </div>

       <div class="tag-group">
          <div class="tag-group-title">Therapeutic Areas</div>
          <div class="tags">
            <span class="tag">Cardiovascular</span>
            <span class="tag">Neurology</span>
            <span class="tag">Rare Disease</span>
            <span class="tag">Oncology</span>
            <span class="tag">Respiratory</span>
            <span class="tag">Microbiome / GI</span>
          </div>
        </div>

        <div class="tag-group">
          <div class="tag-group-title">Small &amp; Large Molecule Modalities</div>
          <div class="tags">
            <span class="tag">Antibody-Protein Fusions</span>
            <span class="tag">Antibody-Drug Conjugates</span>
            <span class="tag">Bispecific Antibodies</span>
            <span class="tag">ASOs</span>
            <span class="tag">GLP1-RAs</span>
            <span class="tag">Novel Sodium Channel Blockers</span>
            <span class="tag">RNAi / siRNA</span>
            <span class="tag">Microbiome Therapeutics</span>
            <span class="tag">Combination Drug / Device Products</span>
            <span class="tag">Inhaled Drug Delivery</span>
            <span class="tag">505(b)(2) Reformulation Products</span>
          </div>
        </div>

        <div class="tag-group">
          <div class="tag-group-title">Regulatory Pathways &amp; Designations</div>
          <div class="tags">
            <span class="tag">505(b)(2)</span>
            <span class="tag">Fast Track</span>
            <span class="tag">Breakthrough Therapy</span>
            <span class="tag">FDA Orphan Drug</span>
            <span class="tag">EMA Orphan Designation</span>
            <span class="tag">EMA ePRIME</span>
          </div>
        </div>

        <div class="tag-group">
          <div class="tag-group-title">Health Authority Interactions</div>
          <div class="tags">
            <span class="tag">FDA Pre-IND</span>
            <span class="tag">FDA EOP1 / EOP2</span>
            <span class="tag">FDA Type B / C / D Meetings</span>
            <span class="tag">EMA Scientific Advice</span>
            <span class="tag">MHRA Scientific Advice</span>
            <span class="tag">BfArM Scientific Advice</span>
            <span class="tag">PMDA Formal Consultation</span>
            <span class="tag">NMPA IND Submissions</span>
            <span class="tag">Australia / TGA CTN Phase 1</span>
            <span class="tag">UK Phase 1 Trials</span>
          </div>
        </div>

        <div class="tag-group">
          <div class="tag-group-title">Focus Areas</div>
          <div class="tags">
            <span class="tag">Regulatory Affairs</span>
            <span class="tag">Medical Writing</span>
            <span class="tag">Clinical Operations</span>
            <span class="tag">Data Management</span>
            <span class="tag">Pharmacovigilance</span>
            <span class="tag">Program Management</span>
            <span class="tag">Vendor Selection &amp; Oversight</span>
          </div>
        </div>

        <!-- TRACK RECORD + GLOBAL REACH -->
        <div style="margin-top:52px;">
          <div style="font-size:10.5px;font-weight:700;letter-spacing:.18em;text-transform:uppercase;color:var(--muted);margin-bottom:20px;">Track Record &amp; Global Reach</div>
          <p class="body-lg" style="font-size:15.5px;margin-bottom:28px;">Over 18 years inside small and midsize biotech across Boston and Cambridge, Amanda has guided programs from first-in-human through FDA approval, exits, and partnerships. A career built entirely in small biotech — working across every function, and knowing how to move programs forward with lean teams and limited resources — spanning 25+ countries and four major regulatory regions.</p>

          <div class="stat-grid" style="grid-template-columns:repeat(3,1fr);margin-bottom:24px;">
            <div class="stat-cell">
              <strong>~10</strong>
              <div class="stat-label">FIH / Phase 1</div>
              <div class="stat-desc">First-in-human &amp; clinical pharmacology</div>
            </div>
            <div class="stat-cell">
              <strong>~8</strong>
              <div class="stat-label">Phase 2 Programs</div>
              <div class="stat-desc">Proof-of-concept &amp; dose-finding</div>
            </div>
            <div class="stat-cell">
              <strong>~5</strong>
              <div class="stat-label">Phase 3 Programs</div>
              <div class="stat-desc">Registrational &amp; confirmatory trials</div>
            </div>
            <div class="stat-cell">
              <strong>17+</strong>
              <div class="stat-label">Years</div>
              <div class="stat-desc">Clinical biotech leadership</div>
            </div>
            <div class="stat-cell">
              <strong>~7</strong>
              <div class="stat-label">FDA INDs Filed</div>
              <div class="stat-desc">Across multiple therapeutic areas</div>
            </div>
            <div class="stat-cell">
              <strong>25+</strong>
              <div class="stat-label">Countries</div>
              <div class="stat-desc">Clinical trial &amp; regulatory submission experience</div>
            </div>
            <div class="stat-cell">
              <strong style="font-size:22px;">FDA</strong>
              <div class="stat-label">Americas</div>
              <div class="stat-desc">Health Canada · ANVISA</div>
            </div>
            <div class="stat-cell">
              <strong style="font-size:22px;">EMA</strong>
              <div class="stat-label">Europe</div>
              <div class="stat-desc">Centralized · MHRA · Swissmedic</div>
            </div>
            <div class="stat-cell">
              <strong style="font-size:22px;">APAC</strong>
              <div class="stat-label">Asia-Pacific</div>
              <div class="stat-desc">PMDA · NMPA · TGA · MFDS · HSA</div>
            </div>
          </div>

          <div class="map-container">
            <div class="map-tooltip" id="map-tooltip"></div>
            <svg id="map-svg" viewBox="0 0 960 500"></svg>
            <div class="map-note">Hover highlighted countries for health authority</div>
          </div>
        </div>

      </div>
    </div>
  </section>

<!-- INDUSTRY TRENDS -->
  <section id="industrytrends">
    <div class="row">
      <div class="label">Clinical Data Fuels Fundraising / M&amp;A</div>
      <div>
        <p class="body-lg">The market has fundamentally reoriented around clinical data. Pharma is spending more than ever on licensing and acquisitions, but concentrating it across <strong>fewer, higher-conviction deals</strong> — and those deals are increasingly targeting companies with clinical-stage assets and de-risked data packages. The inflection point is the value inflection point.</p>

        <div class="stat-grid" style="grid-template-columns:repeat(2,1fr);margin-top:36px;margin-bottom:36px;">
          <div class="stat-cell">
            <strong>74%</strong>
            <span>Of biopharma M&amp;A transactions in full-year 2023 focused on Phase 3 or commercial-stage assets — up from an average of 58% for 2019–2022. Source: IQVIA</span>
          </div>
          <div class="stat-cell">
            <strong>$138B</strong>
            <span>Biopharma M&amp;A in 2025 across 129 deals — described as the strongest M&amp;A year since 2019, driven by patent cliff anxiety and clinical-stage targets. Source: DealForma / J.P. Morgan</span>
          </div>
          <div class="stat-cell">
            <strong>$33.8B</strong>
            <span>Biotech VC deployed in 2025 — across fewer deals than ever, with median round size up 34% vs. 2024 as investors concentrate larger checks into a smaller pool of clinical-stage companies. Source: PitchBook</span>
          </div>
          <div class="stat-cell">
            <strong>75%</strong>
            <span>Of 2025 follow-on equity raises came from companies with Phase 2 or Phase 3 lead programs — investors now require demonstrated clinical validation before committing capital. Source: Pharma Almanac / GlobalData</span>
          </div>
        </div>

        <div class="chart-label">Share of biopharma M&amp;A deals by asset stage &mdash; IQVIA 2019&ndash;2025</div>
        <div class="chart-outer">
          <div style="display:flex;gap:12px;align-items:flex-end;">
            <!-- Y axis -->
            <div style="display:flex;flex-direction:column;justify-content:space-between;height:160px;flex-shrink:0;padding-bottom:1px;">
              <span style="font-size:10px;color:var(--muted);">100%</span>
              <span style="font-size:10px;color:var(--muted);">75%</span>
              <span style="font-size:10px;color:var(--muted);">50%</span>
              <span style="font-size:10px;color:var(--muted);">25%</span>
              <span style="font-size:10px;color:var(--muted);">0%</span>
            </div>

            <!-- Bars -->
            <div style="flex:1;display:flex;align-items:flex-end;gap:8px;height:160px;border-bottom:1px solid var(--rule);border-left:1px solid var(--rule);">

              <!-- 2019: Preclin+Ph1 31%, Ph2 10%, Ph3 31%, Commercial 28% -->
              <div style="flex:1;display:flex;flex-direction:column;height:100%;">
                <div style="flex:1;"></div>
                <div style="height:28%;background:#c8d8e8;"></div>
                <div style="height:31%;background:#6a9dbf;"></div>
                <div style="height:10%;background:#2d6a8f;"></div>
                <div style="height:31%;background:var(--accent);border-radius:2px 2px 0 0;"></div>
              </div>

              <!-- 2022: Preclin+Ph1 26%, Ph2 ~0%, Ph3 29%, Commercial 45% -->
              <div style="flex:1;display:flex;flex-direction:column;height:100%;">
                <div style="flex:1;"></div>
                <div style="height:45%;background:#c8d8e8;"></div>
                <div style="height:29%;background:#6a9dbf;"></div>
                <div style="height:0%;background:#2d6a8f;"></div>
                <div style="height:26%;background:var(--accent);border-radius:2px 2px 0 0;"></div>
              </div>

              <!-- 2023 full year: Preclin+Ph1 26%, Ph2 ~0%, Ph3 18%, Commercial 56% -->
              <div style="flex:1;display:flex;flex-direction:column;height:100%;">
                <div style="flex:1;"></div>
                <div style="height:56%;background:#c8d8e8;"></div>
                <div style="height:18%;background:#6a9dbf;"></div>
                <div style="height:0%;background:#2d6a8f;"></div>
                <div style="height:26%;background:var(--accent);border-radius:2px 2px 0 0;"></div>
              </div>

              <!-- 2024: Preclin+Ph1 26%, Ph2 24%, Ph3 42%, Commercial 8% -->
              <div style="flex:1;display:flex;flex-direction:column;height:100%;">
                <div style="flex:1;"></div>
                <div style="height:8%;background:#c8d8e8;"></div>
                <div style="height:42%;background:#6a9dbf;"></div>
                <div style="height:24%;background:#2d6a8f;"></div>
                <div style="height:26%;background:var(--accent);border-radius:2px 2px 0 0;"></div>
              </div>

              <!-- 2025: Commercial 49%, Ph3 28%, remainder ~23% — dashed/caveated -->
              <div style="flex:1;display:flex;flex-direction:column;height:100%;opacity:.75;">
                <div style="flex:1;"></div>
                <div style="height:49%;background:#c8d8e8;border:1px dashed #aaa;border-bottom:none;box-sizing:border-box;"></div>
                <div style="height:28%;background:#6a9dbf;border-left:1px dashed #aaa;border-right:1px dashed #aaa;box-sizing:border-box;"></div>
                <div style="height:23%;background:var(--accent);opacity:.7;border-radius:2px 2px 0 0;border:1px dashed var(--accent);border-bottom:none;box-sizing:border-box;"></div>
              </div>

            </div>
          </div>

          <!-- X labels -->
          <div style="display:flex;gap:8px;padding:8px 0 4px;padding-left:36px;">
            <div class="bar-lbl">2019</div>
            <div class="bar-lbl">2022</div>
            <div class="bar-lbl">2023</div>
            <div class="bar-lbl">2024</div>
            <div class="bar-lbl" style="color:var(--muted);font-style:italic;">2025*</div>
          </div>

          <!-- Legend -->
          <div style="display:flex;flex-wrap:wrap;gap:16px;padding:12px 0 8px;padding-left:36px;border-top:1px solid var(--rule);margin-top:8px;">
            <div style="display:flex;align-items:center;gap:6px;font-size:11px;color:var(--muted);">
              <div style="width:12px;height:12px;background:var(--accent);border-radius:2px;flex-shrink:0;"></div>
              Preclinical + Phase 1
            </div>
            <div style="display:flex;align-items:center;gap:6px;font-size:11px;color:var(--muted);">
              <div style="width:12px;height:12px;background:#2d6a8f;border-radius:2px;flex-shrink:0;"></div>
              Phase 2
            </div>
            <div style="display:flex;align-items:center;gap:6px;font-size:11px;color:var(--muted);">
              <div style="width:12px;height:12px;background:#6a9dbf;border-radius:2px;flex-shrink:0;"></div>
              Phase 3
            </div>
            <div style="display:flex;align-items:center;gap:6px;font-size:11px;color:var(--muted);">
              <div style="width:12px;height:12px;background:#c8d8e8;border-radius:2px;flex-shrink:0;"></div>
              Commercial
            </div>
            <div style="display:flex;align-items:center;gap:6px;font-size:11px;color:var(--muted);">
              <div style="width:12px;height:12px;border:1px dashed #aaa;border-radius:2px;flex-shrink:0;"></div>
              * 2025 per IQVIA 2026 Outlook; Ph2 share not separately reported
            </div>
          </div>

          <p class="chart-source">Source: IQVIA Biopharma M&amp;A blog series. 2019–2023 from IQVIA "Biopharma M&amp;A Outlook for 2024"; 2024 and 2025 from IQVIA "Biopharma M&amp;A Outlook for 2025/2026." Analysis covers majority-stake acquisitions ≥$1B enterprise value. 2022 interpolated from reported step-changes. Phase 2 share not separately broken out for 2022, 2023, or 2025 by IQVIA; shown as combined with adjacent segments per source methodology.</p>
        </div>

      </div>
    </div>
  </section>

      </div>
    </div>
  </section>

  <!-- CONTACT -->
  <section id="contact">
    <div class="row">
      <div class="label">Contact</div>
      <div>
        <p class="contact-tag">Let's connect.</p>
        <div class="contact-links">
          <a class="contact-link" href="mailto:amanda.gentile@gmail.com">Email Amanda <span class="arr">&#8594;</span></a>
          <a class="contact-link" href="tel:+16176459160">Call Amanda <span class="arr">&#8594;</span></a>
        </div>
      </div>
    </div>
  </section>

  <footer>
    <img class="footer-logo" src="CPCC_logo.png?v=2" alt="Cape Porpoise Clinical Consulting" />
    <div class="footer-meta">
      <p>&#169; <span id="y"></span> Cape Porpoise Clinical Consulting, LLC</p>
      <p>Cambridge, Massachusetts</p>
    </div>
  </footer>

  <script>document.getElementById("y").textContent = new Date().getFullYear();</script>

  <script>
    const countryData = {
      840: { name: "United States",   authority: "FDA" },
      124: { name: "Canada",          authority: "Health Canada" },
      76:  { name: "Brazil",          authority: "ANVISA" },
      372: { name: "Ireland",         authority: "EMA (Centralized)" },
      250: { name: "France",          authority: "EMA (Centralized)" },
      276: { name: "Germany",         authority: "EMA (Centralized)" },
      56:  { name: "Belgium",         authority: "EMA (Centralized)" },
      528: { name: "Netherlands",     authority: "EMA (Centralized)" },
      752: { name: "Sweden",          authority: "EMA (Centralized)" },
      380: { name: "Italy",           authority: "EMA (Centralized)" },
      616: { name: "Poland",          authority: "EMA (Centralized)" },
      203: { name: "Czech Republic",  authority: "EMA (Centralized)" },
      40:  { name: "Austria",         authority: "EMA (Centralized)" },
      208: { name: "Denmark",         authority: "EMA (Centralized)" },
      246: { name: "Finland",         authority: "EMA (Centralized)" },
      300: { name: "Greece",          authority: "EMA (Centralized)" },
      348: { name: "Hungary",         authority: "EMA (Centralized)" },
      724: { name: "Spain",           authority: "EMA (Centralized)" },
      620: { name: "Portugal",        authority: "EMA (Centralized)" },
      642: { name: "Romania",         authority: "EMA (Centralized)" },
      100: { name: "Bulgaria",        authority: "EMA (Centralized)" },
      191: { name: "Croatia",         authority: "EMA (Centralized)" },
      196: { name: "Cyprus",          authority: "EMA (Centralized)" },
      233: { name: "Estonia",         authority: "EMA (Centralized)" },
      428: { name: "Latvia",          authority: "EMA (Centralized)" },
      440: { name: "Lithuania",       authority: "EMA (Centralized)" },
      442: { name: "Luxembourg",      authority: "EMA (Centralized)" },
      470: { name: "Malta",           authority: "EMA (Centralized)" },
      703: { name: "Slovakia",        authority: "EMA (Centralized)" },
      705: { name: "Slovenia",        authority: "EMA (Centralized)" },
      756: { name: "Switzerland",     authority: "Swissmedic" },
      826: { name: "United Kingdom",  authority: "MHRA" },
      643: { name: "Russia",          authority: "Roszdravnadzor" },
      422: { name: "Lebanon",         authority: "Ministry of Health" },
      818: { name: "Egypt",           authority: "Egyptian Drug Authority (EDA)" },
      376: { name: "Israel",          authority: "Ministry of Health (MOH)" },
      392: { name: "Japan",           authority: "PMDA" },
      156: { name: "China",           authority: "NMPA" },
      410: { name: "South Korea",     authority: "MFDS" },
      608: { name: "Philippines",     authority: "FDA-PH" },
      702: { name: "Singapore",       authority: "HSA" },
      36:  { name: "Australia",       authority: "TGA" },
      554: { name: "New Zealand",     authority: "Medsafe" },
    };

    const width = 960, height = 500;
    const svg = d3.select("#map-svg");
    const projection = d3.geoNaturalEarth1()
      .scale(153)
      .translate([width / 2, height / 2]);
    const pathGen = d3.geoPath().projection(projection);
    const tooltip = document.getElementById("map-tooltip");
    const mapContainer = document.querySelector(".map-container");

    fetch("https://cdn.jsdelivr.net/npm/world-atlas@2/countries-110m.json")
      .then(r => r.json())
      .then(world => {
        const countries = topojson.feature(world, world.objects.countries);
        svg.selectAll(".country-path")
          .data(countries.features)
          .enter()
          .append("path")
          .attr("class", d => countryData[+d.id] ? "country-path active" : "country-path")
          .attr("d", pathGen)
          .on("mouseenter", function(event, d) {
            const c = countryData[+d.id];
            if (!c) return;
            tooltip.textContent = `${c.name} — ${c.authority}`;
            tooltip.style.opacity = "1";
          })
          .on("mousemove", function(event) {
            const rect = mapContainer.getBoundingClientRect();
            let tx = event.clientX - rect.left + 14;
            let ty = event.clientY - rect.top - 32;
            if (tx + 300 > rect.width) tx = event.clientX - rect.left - 310;
            if (ty < 0) ty = event.clientY - rect.top + 16;
            tooltip.style.left = tx + "px";
            tooltip.style.top = ty + "px";
          })
          .on("mouseleave", function(event, d) {
            if (countryData[+d.id]) tooltip.style.opacity = "0";
          });
      });
  </script>

</body>
</html>
